| Title |
Ziv-aflibercept in metastatic colorectal cancer
|
|---|---|
| Published in |
Biologics: Targets & Therapy, December 2013
|
| DOI | 10.2147/btt.s39360 |
| Pubmed ID | |
| Authors |
Anuj Patel, Weijing Sun |
| Abstract |
The combination of cytotoxic chemotherapy and antiangiogenic agents has become a conventional treatment option for patients with metastatic colorectal cancer. Ziv-aflibercept is a fusion protein which acts as a decoy receptor for vascular endothelial growth factor (VEGF)-A, VEGF-B, and placental growth factor (PlGF); it was approved in combination with 5-fluorouracil, leucovorin, and irinotecan (FOLFIRI) for the treatment of patients with metastatic colorectal cancer that is resistant to or has progressed after an oxaliplatin-containing fluoropyrimidine-based regimen. Herein we review the role of tumor angiogenesis as the rationale for antiangiogenic therapy, the clinical data associated with ziv-aflibercept, and its current role as a treatment option compared to other antiangiogenic agents, such as bevacizumab and regorafenib. |
X Demographics
The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 1 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Practitioners (doctors, other healthcare professionals) | 1 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 58 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Ecuador | 2 | 3% |
| Portugal | 1 | 2% |
| Unknown | 55 | 95% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Master | 11 | 19% |
| Researcher | 9 | 16% |
| Student > Ph. D. Student | 7 | 12% |
| Student > Bachelor | 5 | 9% |
| Student > Doctoral Student | 5 | 9% |
| Other | 12 | 21% |
| Unknown | 9 | 16% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 15 | 26% |
| Biochemistry, Genetics and Molecular Biology | 7 | 12% |
| Agricultural and Biological Sciences | 7 | 12% |
| Pharmacology, Toxicology and Pharmaceutical Science | 5 | 9% |
| Environmental Science | 2 | 3% |
| Other | 8 | 14% |
| Unknown | 14 | 24% |
Attention Score in Context
This research output has an Altmetric Attention Score of 7. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 07 December 2020.
All research outputs
#5,240,498
of 25,374,647 outputs
Outputs from Biologics: Targets & Therapy
#69
of 284 outputs
Outputs of similar age
#57,527
of 320,964 outputs
Outputs of similar age from Biologics: Targets & Therapy
#2
of 7 outputs
Altmetric has tracked 25,374,647 research outputs across all sources so far. Compared to these this one has done well and is in the 79th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 284 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 6.2. This one has done well, scoring higher than 75% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 320,964 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 81% of its contemporaries.
We're also able to compare this research output to 7 others from the same source and published within six weeks on either side of this one. This one has scored higher than 5 of them.